We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SR Pharma Announces Completion of Additional Toxicology Studies for its Systemically Delivered RNAi Compound

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

SR Pharma plc has announced the successful completion of further toxicology studies for its RNAi product candidate Atu027 which is being developed for systemic cancer indications.

According to the Company, the studies were conducted by an independent clinical research organization and the results allow it to proceed with a full toxicological evaluation of Atu027 in 28-day toxicity studies prior to commencing clinical testing later this year.

The latest pre-clinical toxicology data were presented at a key industry meeting, “RNAi for Target Validation and as a Therapeutic”, in Keystone, Colorado, USA, on 29 January 2007.

Atu027 is designed to inhibit the function of a proprietary kinase protein involved in tumor growth and metastases. In these latest studies the product was administered as a reconstituted lyophilised material and was tested as a 4-hour continuous intravenous infusion using escalating doses. The drug candidate was given every third day over a period of 15 days.

Iain Ross, Chairman of SR Pharma, said: “The positive results from these toxicology studies is another important step forward in the development of Atu027 for systemic cancer indications and keeps us on track to start clinical testing in mid 2007.”